Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Theravance Biopharma Inc
0TBCurrent price
9.15 EUR
0 EUR (0.00%)
Last closed
9.68 USD
Company
www.theravance.com
ISIN
KYG8807B1068
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
437 363 552 USD
Yield for 12 month
-6.45 %
1Y
3Y
5Y
10Y
15Y
0TB
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.2 USDP/E ratio
–Dividend Yield
–Current Year
+57 424 000 USD
Last Year
+51 346 000 USD
Current Quarter
+14 256 000 USD
Last Quarter
+14 503 000 USD
Current Year
+51 372 000 USD
Last Year
+44 757 000 USD
Current Quarter
+12 698 000 USD
Last Quarter
+12 970 000 USD
Key Figures 0TB
1 year
3 years
5 years
10 years
EBITDA
-39 175 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-6.02 %
PEG Ratio
-0.05
Return On Equity TTM
-19.27 %
Wall Street Target Price
13.2 USD
Revenue TTM
62 017 000 USD
Book Value
3.96 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
3.7 %
Dividend Yield
–
Gross Profit TTM
-12 046 000 USD
Earnings per share
-0.95 USD
Diluted Eps TTM
-0.95 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-73.61 %
Dividend Analytics 0TB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 0TB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 0TB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
10.2775
Enterprise Value Revenue
6.2555
Price Sales TTM
7.0523
Enterprise Value EBITDA
-9.6898
Price Book MRQ
2.2581
Financials 0TB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 0TB
For 52 weeks
7.44 USD
11.71 USD
50 Day MA
8.29 USD
Shares Short Prior Month
5 237 799
200 Day MA
8.8 USD
Short Ratio
24.51
Shares Short
5 036 784
Short Percent
20.1 %
BeatStart